ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SI-B037

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 1, since Nov 10, 20261 company-led study, 1 open or runningNext primary completion: Nov 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical11 open or runningphase 1since Nov 10, 2026Nov 10, 2026Nov 2028phase 1 · NCT07940881

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2026First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07940881 · 400 planned · United States

Ahead

  1. Nov 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07940881

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07940881Carcinoma, Non-Small-Cell Lung · United States1RecruitingNov 2028400

How it is read

Names in the registry

  • “SI-B037”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 18, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.